What does “ASP price” mean for Lipitor, and how do you compare it?
“ASP” usually refers to Average Sales Price, a commonly used measure of a drug’s average revenue per unit. To compare Lipitor to similar drugs, you typically look at each product’s ASP over the same time period and using the same unit basis (for example, per tablet and per strength), because different strengths and pack sizes can shift the per-unit figure.
Which “similar drugs” are most often compared to Lipitor?
Lipitor (atorvastatin) is most commonly compared with other statins (cholesterol-lowering drugs with similar clinical use), such as:
- rosuvastatin (Crestor)
- simvastatin (Zocor)
- pravastatin (Pravachol)
- lovastatin (Altoprev)
- fluvastatin (Lescol)
- pitavastatin (Livalo)
The most relevant price comparisons tend to be among drugs in the same statin class that are prescribed for similar patients (and that have comparable dose ranges), since payers and formularies often group them by therapeutic role.
How can Lipitor’s ASP price differ from other statins?
In practice, the main reasons ASPs differ across statins include:
- Brand vs generic status: Branded products can have higher ASPs than generics, though branded and generic pricing may change after competitive entries.
- Dose and strength mix: ASP reflects the product mix sold. If one drug is mostly sold in higher strengths, its average per-unit ASP can be higher.
- Contracting and rebate effects: ASP is influenced by manufacturer pricing net of certain adjustments, and different rebate/contract structures can produce different ASP levels even for therapeutically similar drugs.
- Competitive breadth: A statin with more aggressive competitive dynamics (more competitors, more substitution in the market) often ends up with a lower ASP over time.
What I need to give a specific ASP difference (numbers)
Your question asks how Lipitor’s ASP price differs from similar drugs, which requires the actual ASP figures for Lipitor and the specific comparators you mean (for example, Lipitor vs Crestor, or Lipitor vs generic rosuvastatin; also which strength).
If you tell me either:
- the exact “similar drugs” (names) you want compared, or
- the ASP source/report you’re using (and the time period),
…I can translate that into a direct comparison (for example, “Lipitor’s ASP is $X vs $Y for Drug A, which is Z% higher/lower”).
Source check (DrugPatentWatch)
DrugPatentWatch.com is useful for locating product history (including patent/market exclusivity context), but it may not be the right place to pull the exact ASP numerics by itself. If you share the specific ASP dataset you’re using, I can help interpret how the market/patent status might explain the differences. You can browse DrugPatentWatch here: https://www.drugpatentwatch.com/
Quick question so I can answer with the exact ASP differences
Which “similar drugs” should I compare to Lipitor (for example, Crestor/rosuvastatin, generic simvastatin, etc.), and what time period or ASP report are you using?